The evidence, the dosing rationale, the safety profile, and the ability to attribute any effect all get weaker as ingredients are added, because the number of unstudied interactions grows
Cardiovascular disease remains the leading cause of morbidity and mortality in these populations, underscoring the necessity for treatments that not only manage blood glucose and body weight but also confer cardiovascular benefits
Individual results are not established and should not be assumed
Clinical red flags Dramatic changes in effectiveness between batches
Metformin has the benefits of weight neutrality, improved lipid profile, and reduced platelet aggregation, which can improve vascular complications of diabetes
Shed also offers NAD+ alongside its GLP-1 line, which lets patients interested in longevity and metabolic support consolidate both on a single platform